Barclays
CNTA

Barclays’s Centessa Pharmaceuticals CNTA Stock Holding History

Barclays’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$275K Buy
6,922
+5,814
+525% +$149K ﹤0.01% 3516
2025
Q4 		$27.7K Sell
1,108
-3,860
-78% -$97.8K ﹤0.01% 4835
2025
Q3 		$120K Sell
4,968
-2,551
-34% -$45.3K ﹤0.01% 4558
2025
Q2 		$98.8K Sell
7,519
-30,655
-80% -$388K ﹤0.01% 4572
2025
Q1 		$549K Buy
38,174
+32,872
+620% +$538K ﹤0.01% 3474
2024
Q4 		$88.8K Buy
5,302
+4,952
+1,415% +$82K ﹤0.01% 4623
2024
Q3 		$5.6K Buy
+350
New +$4.29K ﹤0.01% 5021
2024
Q1 		– Sell
-6,400
Closed -$50.9K – 5125
2023
Q4 		$50.9K Hold
6,400
– – ﹤0.01% 4774
2023
Q3 		$41.4K Hold
6,400
– – ﹤0.01% 3947
2023
Q2 		$39.6K Hold
6,400
– – ﹤0.01% 3930
2023
Q1 		$24.6K Buy
+6,400
New +$23.4K ﹤0.01% 4619

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Barclays's CNTA Position: Q1 2026 in Review

Barclays increased its Centessa Pharmaceuticals (CNTA) stake by 525% in Q1 2026, buying an estimated $149K and bringing the position to 6,922 shares worth $275K. The position accounts for ﹤0.01% of the portfolio, ranked #3516.

Barclays first reported a position in CNTA in Q1 2023 and has held it in 11 quarters since. The position peaked at $549K in Q1 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Barclays held 6,922 shares of Centessa Pharmaceuticals worth $275K as of Q1 2026.
  • Barclays bought 5,814 Centessa Pharmaceuticals shares in Q1 2026, an estimated $149K.
  • Centessa Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3516 holding.
  • Barclays first reported a position in Centessa Pharmaceuticals in Q1 2023 and has held it in 11 quarters since.
  • Barclays's Centessa Pharmaceuticals position peaked at $549K in Q1 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.